E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hidradenitis suppurativa |
Hidradenitis supurativa |
|
E.1.1.1 | Medical condition in easily understood language |
acne inversa or maladie de Verneuil |
acné inverso o enfermedad de Verneuil |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020041 |
E.1.2 | Term | Hidradenitis suppurativa |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of the investigational treatments when compared to placebo, in moderate to severe inflammatory HS Patients |
Evaluar la eficacia de los tratamientos en investigación comparados con placebo, en pacientes con HS inflamatoria de moderada a grave |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of the investigational treatments in Patients with moderate to severe hidradenitis suppurativa (HS) |
Evaluar la seguridad y tolerabilidad de los tratamientos en investigación en pacientes con hidradenitis supurativa (HS) de moderada a grave |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female, age 18-65 years, at least 50 kg body weight with moderate to severe HS - Clinically diagnosed HS for at least 12 months prior to screening - For Cohort A (iscalimab): at least 5 inflammatory lesions, no more than 10 fistulae and at least two anatomical area involved with HS lesions - For Cohort B (LYS006): at least 3 inflammatory lesions; no more than 10 fistulae and at least two anatomical areas involved with HS lesions
Other protocol-defined inclusion criteria may apply |
-Pacientes de ambos sexos de 18 a 65 años de edad, con peso corporal mínimo de 50 kg con HS de moderada a grave -Diagnóstico clínico de HS durante al menos los 12 meses anteriores a la selección. -Para la cohorte A (iscalimab): Un total de al menos 5 lesiones inflamatorias, no más de 10 fístulas, y al menos dos áreas anatómicas deben presentar lesiones de HS. -Para la cohorte B(LYS006): Un total de al menos 3 lesiones inflamatorias, no más de 10 fístulas, y al menos dos áreas anatómicas deben presentar lesiones de HS.
Para mas criterios por favor consultar protocolo |
|
E.4 | Principal exclusion criteria |
- Use of other investigational drugs at the time of screening, or within 30 days or 5 half lives of randomization, whichever is longer; or longer if required by local regulations; or longer if required by local regulations - Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for the subsequent 14 weeks after the last study drug administration for Cohort A (iscalimab) and the subsequent 2 weeks after the last study drug administration for Cohort B (LYS006). - Pregnant or nursing (lactating) women at screening or randomization
Other protocol-defined exclusion criteria may apply |
- Uso de otros fármacos en investigación en el momento de la selección, o durante los 30 días o 5 vidas medias anteriores a la aleatorización, aquello que sea más largo, o durante más tiempo si así lo exige la normativa local. -Mujeres en edad fértil (definidas como toda mujer fisiológicamente capaz de quedarse embarazada), salvo que estén utilizando métodos anticonceptivos altamente eficaces durante la administración de la dosis y durante un mínimo de 14 semanas después de la última administración del fármaco del estudio en la cohorte A (iscalimab) y un mínimo de 2 semanas después de la última administración del fármaco del estudio en la cohorte B (LYS006). -Mujeres embarazadas o en periodo de lactancia en la selección o la aleatorización
Para mas criterios por favor consultar protocolo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients achieving hidradenitis suppurativa clinical response after 16 weeks of treatment |
Proporción de pacientes que alcanzan la respuesta clínica en hidradenitis supurativa después de 16 semanas de tratamiento |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Number and severity of adverse events - Physical exam, vital signs, safety laboratory measurements, ECGs |
-Número e intensidad de los AA -La exploración física, constantes vitales, mediciones de seguridad de laboratorio y ECG |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At baseline and repeatedly until study completion |
En la basal y de manera repetida hasta la visita de finalización del estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Estudio plataforma: se estudian múltiples ttos específicos en investigación en una misma enfermedad |
Platform study: studies multiple targeted investigational treatments in context of single disease |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Belgium |
Czech Republic |
Denmark |
France |
Germany |
Hungary |
Iceland |
Netherlands |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Último paciente, última visita |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |